Brainstorm Cell Therapeutics Inc

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a clinical-stage biotechnology company developing autologous adult stem cell therapies for neurodegenerative diseases. Its proprietary NurOwn platform uses autologous bone marrow-derived mesenchymal stem cells (MSCs) that are expanded and differentiated ex vivo to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn is the company's lead investigational therapy for amyotrophic lateral sclerosis (ALS), with Orphan Drug designation from both the FDA and the European Medicines Agency. The company has completed a Phase 3 trial in ALS and is preparing to launch a Phase 3b ENDURANCE trial under a Special Protocol Assessment agreement with the FDA. BrainStorm has also completed a Phase 2 trial of MSC-NTF cells in progressive multiple sclerosis and is advancing a proprietary allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company is pre-revenue and trades on the OTCQB marketplace. Updated Aug 14, 2026